A detailed history of Cetera Investment Advisers transactions in Bio Line Rx Ltd. stock. As of the latest transaction made, Cetera Investment Advisers holds 71,667 shares of BLRX stock, worth $45,866. This represents 0.0% of its overall portfolio holdings.

Number of Shares
71,667
Previous 18,030 297.49%
Holding current value
$45,866
Previous $20,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 22, 2024

BUY
$0.56 - $0.86 $30,036 - $46,127
53,637 Added 297.49%
71,667 $40,000
Q1 2024

May 24, 2024

BUY
$1.03 - $1.56 $18,570 - $28,126
18,030 New
18,030 $20,000
Q4 2023

Feb 13, 2024

SELL
$1.31 - $1.86 $5,208 - $7,395
-3,976 Reduced 26.76%
10,884 $17,000
Q3 2023

Nov 14, 2023

BUY
$1.23 - $2.45 $731 - $1,457
595 Added 4.17%
14,860 $27,000
Q2 2023

Aug 09, 2023

SELL
$0.96 - $1.78 $5,508 - $10,213
-5,738 Reduced 28.69%
14,265 $22,000
Q1 2023

May 15, 2023

BUY
$0.56 - $0.89 $11,201 - $17,802
20,003 New
20,003 $17,000

Others Institutions Holding BLRX

About BioLineRx Ltd.


  • Ticker BLRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,524,500
  • Market Cap $39.4M
  • Description
  • BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...
More about BLRX
Track This Portfolio

Track Cetera Investment Advisers Portfolio

Follow Cetera Investment Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cetera Investment Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Cetera Investment Advisers with notifications on news.